Abstract
Tumor suppressor p53 lacks conventional drug binding pockets that would facilitate rescue of cancer-driving mutations. In this issue, Chen etal. discover a new role for an old drug, arsenic trioxide, in binding and stabilizing p53. The arsenic atom binds in a conserved, cryptic site and reactivates multiple p53 mutants.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
